| Market withdrawal of new molecular entities approved in the United States from 1980 to 2009 ZP Qureshi, E Seoane‐Vazquez, R Rodriguez‐Monguio, KB Stevenson, ... Pharmacoepidemiology and drug safety 20 (7), 772-777, 2011 | 198 | 2011 |
| A flexible, computationally efficient method for fitting the proportional hazards model to interval-censored data L Wang, CS McMahan, MG Hudgens, ZP Qureshi Biometrics 72 (1), 222-231, 2016 | 140 | 2016 |
| Regulatory and clinical considerations for biosimilar oncology drugs CL Bennett, B Chen, T Hermanson, MD Wyatt, RM Schulz, ... The Lancet Oncology 15 (13), e594-e605, 2014 | 135 | 2014 |
| Gadolinium-induced nephrogenic systemic fibrosis: the rise and fall of an iatrogenic disease CL Bennett, ZP Qureshi, AO Sartor, LAB Norris, A Murday, S Xirasagar, ... Clinical kidney journal 5 (1), 82-88, 2012 | 105 | 2012 |
| Ticlopidine-, clopidogrel-, and prasugrel-associated thrombotic thrombocytopenic purpura: a 20-year review from the Southern Network on Adverse Reactions (SONAR) S Jacob, BL Dunn, ZP Qureshi, N Bandarenko, HC Kwaan, DK Pandey, ... Seminars in thrombosis and hemostasis 38 (08), 845-853, 2012 | 99 | 2012 |
| Acquired Idiopathic ADAMTS13 Activity Deficient Thrombotic Thrombocytopenic Purpura in a Population from Japan M Matsumoto, CL Bennett, A Isonishi, Z Qureshi, Y Hori, M Hayakawa, ... PloS one 7 (3), e33029, 2012 | 91 | 2012 |
| Effects of women’s autonomy on maternal healthcare utilization in Bangladesh: Evidence from a national survey MR Haider, ZP Qureshi, MM Khan Sexual & reproductive healthcare 14, 40-47, 2017 | 77 | 2017 |
| Generic oncology drugs: are they all safe? YT Yang, S Nagai, BK Chen, ZP Qureshi, AA Lebby, S Kessler, ... The lancet oncology 17 (11), e493-e501, 2016 | 52 | 2016 |
| A Review of Safety, Efficacy, and Utilization of Erythropoietin, Darbepoetin, and Peginesatide for Patients with Cancer or Chronic Kidney Disease: A Report from the Southern … CL Bennett, DM Spiegel, IC Macdougall, LA Norris, ZP Qureshi, O Sartor, ... Seminars in thrombosis and hemostasis 38 (08), 783-796, 2012 | 52 | 2012 |
| Clinical practice patterns on the use of magnesium sulphate for treatment of pre‐eclampsia and eclampsia: a multi‐country survey Q Long, OT Oladapo, S Leathersich, JP Vogel, G Carroli, P Lumbiganon, ... BJOG: An International Journal of Obstetrics & Gynaecology 124 (12), 1883-1890, 2017 | 51 | 2017 |
| Fluoroquinolone-related neuropsychiatric and mitochondrial toxicity: a collaborative investigation by scientists and members of a social network. K Kaur, R Fayad, A Saxena, N Frizzell, A Chanda, S Das, S Chatterjee, ... The Journal of community and supportive oncology 14 (2), 54-65, 2016 | 45 | 2016 |
| Linking drugs to obscure illnesses: lessons from pure red cell aplasia, nephrogenic systemic fibrosis, and Reye’s syndrome. a report from the Southern Network on Adverse … CL Bennett, KM Starko, HS Thomsen, S Cowper, O Sartor, IC Macdougall, ... Journal of general internal medicine 27, 1697-1703, 2012 | 42 | 2012 |
| Safety and effectiveness of daptomycin across a hospitalized obese population: results of a multicenter investigation in the southeastern United States PB Bookstaver, CM Bland, ZP Qureshi, CM Faulkner‐Fennell, ... Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 33 (12 …, 2013 | 40 | 2013 |
| Polysorbate 80 hypersensitivity reactions: a renewed call to action LAB Norris, ZP Qureshi, PB Bookstaver, DW Raisch, O Sartor, H Chen, ... Community Oncology 7 (9), 425-428, 2010 | 40 | 2010 |
| Description of anaphylactic reactions to paclitaxel and docetaxel reported to the FDA, with a focus on the role of premedication DW Raisch, W Campbell, V Garg, ZP Qureshi, PB Bookstaver, LAB Norris, ... Expert Opinion on Drug Safety 10 (4), 521-528, 2011 | 37 | 2011 |
| Ticlopidine-associated ADAMTS13 activity deficient thrombotic thrombocytopenic purpura in 22 persons in Japan: a report from the Southern Network on Adverse Reactions (SONAR) CL Bennett, S Jacob, BL Dunn, P Georgantopoulos, XL Zheng, ... British journal of haematology 161 (6), 896, 2013 | 34 | 2013 |
| Melanoma complicating treatment with natalizumab for multiple sclerosis: A report from the Southern Network on Adverse Reactions (SONAR) RA Sabol, V Noxon, O Sartor, JR Berger, Z Qureshi, DW Raisch, ... Cancer medicine 6 (7), 1541-1551, 2017 | 33 | 2017 |
| Development and feasibility of an academic detailing intervention to improve prescription drug monitoring program use among physicians KS Barth, S Ball, RS Adams, R Nikitin, NR Wooten, ZP Qureshi, ... Journal of Continuing Education in the Health Professions 37 (2), 98-105, 2017 | 30 | 2017 |
| WHO Multicountry Survey on Maternal Newborn Health Research Network. Overview of abortion cases with severe maternal outcomes in the WHO Multicountry Survey on Maternal and … M Dragoman, WR Sheldon, Z Qureshi, J Blum, B Winikoff, B Ganatra BJOG 121 (Suppl 1), 25-31, 2014 | 30 | 2014 |
| Rituximab and biosimilars–equivalence and reciprocity ZP Qureshi, JS Magwood, S Singh, CL Bennett Biosimilars, 19-25, 2013 | 29 | 2013 |
Oliver SartorTulane UniversityVerified email at tulane.edu
